Elisabetta Verdun di Cantogno

Statistics

Publications

Citations

400

H-Index

Active since

2010

Affiliations

Merck Serono S.A. (Switzerland)(Current)

Ono Pharmaceutical (United States)

Research & Development Institute

University of British Columbia

University of Ottawa

Elisabetta Verdun di Cantogno is an author at Merck Serono S.A. (Switzerland) specializing in neurology, multiple sclerosis, and relapsing-remitting multiple sclerosis treatment.

Publications per year

2010–2023

Publications

Subcutaneous Interferon Beta-1a in Pediatric Multiple Sclerosis

Sílvia Tenembaum, Brenda Banwell, Daniela Pohl et al. · Journal of Child Neurology · 2013 · 84 citations · Full text

Medicine, Neurology, Pediatrics +16

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15

Ludwig Kappos, Jens Kühle, Juha Multanen et al. · Journal of Neurology Neurosurgery & Psychiatry · 2015 · 84 citations · Full text

Medicine, Neurology, Pharmacotherapy +15

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study

Gavin Giovannoni, Jorge Correale, Gilles Edan et al. · Multiple Sclerosis Journal · 2023 · 49 citations · Full text

Nursing, Neurology, Disability Management +16

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study

Virginia Devonshire, Txomin Arbizu, Björn Borre et al. · BMC Neurology · 2010 · 47 citations · Full text

Pharmacy, Neurology, Drug Delivery +7

Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deﬁcits in multiple sclerosis.

Francesco Mori, Hajime Kusayanagi, Fabio Buttari et al. · PubMed · 2013 · 46 citations

Life Sciences, Neurology, Neuroscience +17

1–5 of 9